Prior to joining Bristol-Myers Squibb, Giovanni spent 12 years with Abbott Laboratories in a number of leadership positions.īorn and educated in Italy, Giovanni received his M.D. In 2010, he was named senior vice president, Global Commercialization, Oncology and Immunology, before becoming president of the company’s U.S. to assume the role of senior vice president, U.S. In 2004, he was appointed senior vice president, European Marketing and Brand Commercialization. Other search options: Filter and sort Full text search. Amicus curiae briefs are listed by plaintiff's name. He assumed added responsibility for Greece and Israel in 2001, and for South East Europe in 2003. Cases are listed alphabetically by the last name of individual defendants, by company name, or by the entity's first name. Giovanni joined Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. This was preceded by his work as the company’s chief commercial officer. Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. As a leader, he is focused on the business value of a company culture that promotes and rewards diversity and inclusion. With a background as a physician, Giovanni has helped strengthen the company’s patient-focused culture - one driven by innovation, speed, accountability and passion. Under his leadership, BMS is evolving its operating model in order to increase speed and competitiveness. In May 2017, he assumed the role of chairman of the board.Īs CEO, Giovanni has led the company’s focus on researching and developing transformational medicines, which includes a leading portfolio of immunotherapies that are fundamentally changing the way cancer is treated. has been chief executive officer of Bristol-Myers Squibb since May 2015 and has been serving on the company’s Board of Directors since June 2014. Visit the Bristol Myers website for complete details.Giovanni Caforio, M.D. Our financial strength, dedicated workforce, and proven ability to execute will enable us to continue to advance our pipeline, invest in future sources of innovation, and position the company for sustained growth.” I am confident in our ability to execute against our key milestones in 2022, including three planned first-in-class launches with relatlimab plus nivolumab fixed-dose combination, mavacamten, and deucravacitinib. “2021 was a pivotal year for our company as we achieved significant regulatory and clinical milestones and positioned the company to successfully renew our portfolio. “I am proud of how our company performed in 2021, helping more patients across our therapeutic areas while achieving 9% revenue and 17% non-GAAP EPS growth, respectively,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. NEW YORK ( STL.News) Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company’s pipeline that further progressed the company’s portfolio renewal. Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021 Reports Fourth Quarter Revenues of $12.0 Billion Full-Year Revenues of $46.4 Billion Posts Fourth Quarter Earnings Per Share of $1.07 and Non-GAAP EPS of $1.83 Posts Full-Year Earnings Per Share of $3.12 and Non-GAAP EPS of $7.51 Delivers Strong Revenues for Eliquis, Immuno-Oncology, and New Product Portfolios Advances Pipeline with Achievement of Significant Clinical and Regulatory Milestones Builds Strong Foundation for Portfolio Renewal Announces $15 Billion Share Repurchase Authorization $5 Billion Accelerated Share Repurchase Agreement to be Executed During the First Quarter 2022 Provides GAAP and More Detailed Non-GAAP Financial Guidance for 2022 Reaffirms Long-term Financial Targets
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |